Burning Rock Biotech Ltd
NASDAQ:BNR
FCF Margin
Free Cash Flow Margin
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
FCF Margin Across Competitors
| Country | Company | Market Cap |
FCF Margin |
||
|---|---|---|---|---|---|
| CN |
|
Burning Rock Biotech Ltd
NASDAQ:BNR
|
31.4m USD |
-19%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-15 953%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
323.9B USD |
27%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
149.7B USD |
32%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
133.8B USD |
33%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.5B USD |
-11%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-394%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
119.7B AUD |
12%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
64B USD |
21%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-30%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.8B USD |
-3%
|
Burning Rock Biotech Ltd
Glance View
Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.
See Also
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
Based on Burning Rock Biotech Ltd's most recent financial statements, the company has FCF Margin of -19%.
You don't have any saved screeners yet